QRG Capital Management Inc. Buys 27,283 Shares of IQVIA Holdings Inc. $IQV

Key Points

• QRG Capital Management increased its IQVIA position by 87.7% in the second quarter, purchasing 27,283 additional shares for a total holding valued at approximately $11.3 million. Institutional investors own 89.62% of the company.
• IQVIA reported quarterly results above expectations, with earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion, up 8.7% year over year.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $248, while insiders sold 15,581 shares worth about $3.8 million over the past three months.

QRG Capital Management Inc. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 87.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,407 shares of the medical research company's stock after purchasing an additional 27,283 shares during the period. QRG Capital Management Inc.'s holdings in IQVIA were worth $11,285,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. BlackRock Inc. purchased a new stake in shares of IQVIA during the 2nd quarter worth approximately $2,811,292,000. Norges Bank purchased a new position in shares of IQVIA in the 4th quarter worth $497,445,000. Victory Capital Management Inc. increased its holdings in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock worth $377,670,000 after buying an additional 1,614,063 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of IQVIA in the 2nd quarter worth about $240,911,000. Finally, Bank of America Corp DE purchased a new stake in shares of IQVIA during the 2nd quarter valued at about $235,551,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Down 0.8%

NYSE:IQV opened at $268.05 on Thursday. The stock has a fifty day simple moving average of $246.41 and a 200-day simple moving average of $201.57. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $44.12 billion, a price-to-earnings ratio of 33.26, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $277.40.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.56 EPS for the current year.

Insider Activity at IQVIA

In other news, insider James G. Berkshire sold 2,668 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Bhavik Patel sold 1,855 shares of the company's stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares of the company's stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock worth $3,796,021 over the last three months. Corporate insiders own 1.70% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on IQV shares. TD Cowen lifted their price target on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Royal Bank Of Canada raised their price objective on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. HSBC reissued a "buy" rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $248.00.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.